Admedus will be attending the American Association for Thoracic Surgery (AATS) Aortic Symposium 2016 May 12–13 in New York City, USA and the 96th AATS Annual Meeting taking place from 14–18 May in Baltimore, USA.
“CardioCel is fast becoming the surgeon-preferred material for reconstruction and repairs in the aortic and mitral valve repair market, with the product providing a genuine alternative for patients compared to bio-prosthetic valves,” says Admedus managing director, Lee Rodne.
Prior to the AATS Symposium in New York, Admedus will be hosting a “Meet the Surgeon” investor day on Wednesday, 11 May to discuss the future of valve repair and to share knowledge on using CardioCel for mitral and aortic valve repair and reconstructions.
The global market for cardiovascular disease is estimated to grow to US$4.8 billion by 2020. In the United States, surgeons currently perform approximately 106,000 heart valve operations each year.
Admedus continues to progress its aortic valve reconstruction post-market study with several centres globally recruiting patients. An update on the study is anticipated in the coming months. The study is designed to further show the use of CardioCel in repairing aortic heart valves and its potential for improved patient outcomes compared to bio-prosthetic valves.